© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Integrin 
3 Leu33Pro Homozygosity and Risk of Cancer
Affiliations of authors: S. E. Bojesen, Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark; A. Tybjærg-Hansen, The Copenhagen City Heart Study, Bispebjerg University Hospital and Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; B. G. Nordestgaard, Department of Clinical Biochemistry, Herlev University Hospital, and The Copenhagen City Heart Study, Bispebjerg University Hospital.
Correspondence to: Børge G. Nordestgaard, M.D., D.M.Sc., Dept. of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark (e-mail: brno{at}herlevhosp.kbhamt.dk).
Background: Increased tumor cell expression of integrins containing the 
3 subunit is associated with increased progression to invasive tumors, whereas inhibition of 3 integrin expression and/or function may reduce tumor growth and metastasis. The Leu33Pro polymorphism of the 3 subunit modulates the function of 
IIb3 integrin. We examined whether this polymorphism influences cancer risk. Methods: Using participants (n = 9242) from the Copenhagen City Heart Study with 24 years of follow-up and endpoints from the Danish Cancer Registry, we assessed the risk of all cancers and of 27 cancer types in individuals who carry the Leu33Pro polymorphism (heterozygotes and homozygotes) relative to those without the polymorphism (non-carriers). Relative risks (RRs) of cancer and 95% confidence intervals (CIs) were calculated by Cox proportional hazards regression analysis. Differences in cumulative cancer incidence (per 10 000 person-years) were tested using log-rank statistics. Statistical tests were two-sided. Results: Among the participants, 70.0% were non-carriers, 27.3% were heterozygotes, and 2.7% were homozygotes. We detected 1296 participants with a first cancer. Cumulative incidences in non-carriers, heterozygotes, and homozygotes were 81, 83, and 112, respectively (homozygotes versus non-carriers, P = .02). The age-adjusted RR of all cancers in homozygotes relative to non-carriers was 1.4 (95% CI = 1.1 to 1.9). Incidences in non-carriers, heterozygotes, and homozygotes were 3, 4, and 16 for ovarian cancer; 19, 24, and 36 for breast cancer; and 2, 3, and 7 for melanoma (homozygotes versus non-carriers; P = .002, P = .06, and P = .03, respectively). The age-adjusted RR in homozygotes relative to non-carriers was 4.7 (95% CI = 1.6 to 14) for ovarian cancer, 1.9 (95% CI = 1.0 to 3.7) for breast cancer, and 3.5 (95% CI = 1.1 to 12) for melanoma. Adjustment for other cancer risk factors did not alter these results. Heterozygotes did not differ from non-carriers with respect to cancer risk. Conclusion: Individuals homozygous for the Leu33Pro polymorphism of the 3 integrin subunit have an increased cancer risk.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
-
Re: Integrin 3 Leu33Pro Homozygosity and Risk of Cancer
- Qianren Jin, Kari Hemminki, Ewa Grzybowska, Rüdiger Klaes, Magnus Söderberg, and Asta Försti
J Natl Cancer Inst 2004 96: 234-235.[Extract] [Full Text] [PDF]
-
RESPONSE: Re: Integrin 3 Leu33Pro Homozygosity and Risk of Cancer
- Stig E. Bojesen, Anne Tybjærg-Hansen, and Børge G. Nordestgaard
J Natl Cancer Inst 2004 96: 235.[Extract] [Full Text] [PDF]
-
Re: Integrin 3 Leu33Pro Homozygosity and Risk of Cancer
- Shan Wang-Gohrke and Jenny Chang-Claude
J Natl Cancer Inst 2005 97: 778-779.[Extract] [Full Text] [PDF]
-
RESPONSE: Re: Integrin 3 Leu33Pro Homozygosity and Risk of Cancer
- Stig Egil Bojesen, Anne Tybjærg-Hansen, and Børge Grønne Nordestgaard
J Natl Cancer Inst 2005 97: 779-780.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  A. Brendle, H. Lei, A. Brandt, R. Johansson, K. Enquist, R. Henriksson, K. Hemminki, P. Lenner, and A. Forsti Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker Carcinogenesis, July 1, 2008; 29(7): 1394 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Dombernowsky, M. Weischer, K. H. Allin, S. E. Bojesen, A. Tybjjrg-Hansen, and B. G. Nordestgaard Risk of Cancer by ATM Missense Mutations in the General Population J. Clin. Oncol., June 20, 2008; 26(18): 3057 - 3062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Cerhan, S. M. Ansell, Z. S. Fredericksen, N. E. Kay, M. Liebow, T. G. Call, A. Dogan, J. M. Cunningham, A. H. Wang, W. Liu-Mares, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma Blood, December 15, 2007; 110(13): 4455 - 4463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Orsted, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population J. Exp. Med., June 11, 2007; 204(6): 1295 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jakubowska, J. Gronwald, J. Menkiszak, B. Gorski, T. Huzarski, T. Byrski, L. Edler, J. Lubinski, R. J Scott, and U. Hamann Integrin {beta}3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk J. Med. Genet., June 1, 2007; 44(6): 408 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huveneers, I. van den Bout, P. Sonneveld, A. Sancho, A. Sonnenberg, and E. H.J. Danen Integrin {alpha}v{beta}3 Controls Activity and Oncogenic Potential of Primed c-Src Cancer Res., March 15, 2007; 67(6): 2693 - 2700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weischer, S. E. Bojesen, A. Tybjaerg-Hansen, C. K. Axelsson, and B. G. Nordestgaard Increased Risk of Breast Cancer Associated With CHEK2*1100delC J. Clin. Oncol., January 1, 2007; 25(1): 57 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S E Bojesen, S K Kjaer, E V S Hogdall, B L Thomsen, C K Hogdall, J Blaakaer, A Tybjaerg-Hansen, and B G Nordestgaard Increased risk of ovarian cancer in integrin {beta}3 Leu33Pro homozygotes Endocr. Relat. Cancer, December 1, 2005; 12(4): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard RESPONSE: Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer J Natl Cancer Inst, May 18, 2005; 97(10): 779 - 780. [Full Text] [PDF]
|
|
|
|
|
|
S. Wang-Gohrke and J. Chang-Claude Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer J Natl Cancer Inst, May 18, 2005; 97(10): 778 - 779. [Full Text] [PDF]
|
|
|
|
 |
|
 M Dahl, B G Nordestgaard, and N Seersholm {alpha}1-Antitrypsin genotype unaffected by age * Authors' reply Thorax, March 1, 2005; 60(3): 258 - 259. [Full Text] [PDF]
|
|
|
|
|
|
M. Dahl, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency J. Exp. Med., May 17, 2004; 199(10): 1391 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Jin, K. Hemminki, E. Grzybowska, R. Klaes, M. Soderberg, and A. Forsti Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer J Natl Cancer Inst, February 4, 2004; 96(3): 234 - 235. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard RESPONSE: Re: Integrin {beta}3 Leu33Pro Homozygosity and Risk of Cancer J Natl Cancer Inst, February 4, 2004; 96(3): 235 - 235. [Full Text] [PDF]
|
|